Straumann reports full-year revenues of CHF 686m *Solid growth in North America offsets sluggish Europe, while Asia/Pacific remains stable *Gross profit margin improves 130 base points to 78%; EBIT margin at 15%, excluding exceptionals *Reported profits reduced by impairment and other exceptional charges1 *Vision 2020 and market fundamentals intact *Neodent performs in line with expectations *Unchanged dividend of CHF 3.75 per share proposed *New CEO to drive performance KEY FIGURES (in CHF million) FY 2012 FY 2012 FY 2011 FY 2011 excluding excluding reported reported exceptionals1 exceptionals1 Revenue 686.3 693.6 Change in CHF% (1.1) (6.0) Change in l.c.% (1.6) 4.1 Change in l.c. % (excl. iTero2) (1.0) Gross profit 531.5 534.4 528.5 Margin in % 77.5 77.9 76.2 Change in % 0.6 1.1 (10.0) EBITDA 117.4 130.4 157.4 Margin in % 17.1 19.0 22.7 Change in % (25.4) (17.2) (25.7) Operating profit (EBIT) 61.0 99.5 79.9 120.1 Margin in % 8.9 14.5 11.5 17.3 Change in % (23.7) (17.2) (51.4) (26.9) Net profit 36.4 71.0 Margin in % 5.3 10.2 Change in % (48.6) (45.9) Basic EPS (in CHF) 2.36 4.54 Free cash flow3 95.2 121.1 Margin in % 13.9 17.5 Change in % (21.4) (21.5) Number of employees (year-end) 2517 2452 Basel, 21 February 2013: In 2012, the Straumann Group achieved revenue of CHF 686 million, which was almost 2% below the prior year in local currencies (l.c.) or just 1% below in Swiss francs, reflecting the first overall positive currency effect since 2007. North America was the key revenue driver, complemented by double-digit growth in China and Latin America. Unfortunately, these solid performances were not enough to compensate for sluggish sales in Europe, Japan and the Middle East. Despite an improvement of 130 base points in the gross margin (78%), reported operating income (EBIT) dipped to CHF 61 million corresponding to a reported margin of 9%. Excluding exceptionals (i.e. an impairment charge of CHF 21 million related to the regenerative business, and one-time charges of CHF 18 million due to cost optimization initiatives and severances) operating income would have reached CHF 100 million (versus CHF 120 million in 2011), with a corresponding margin of almost 15%. Reported net profit reached CHF 36 million and basic earnings per share amounted to CHF 2.36 (CHF 4.54 in 2011). Gilbert Achermann, Chairman & Acting CEO, commented: "We continued to grow our business in North America, and other key growth markets like China and Brazil, but their strong performances were not enough to offset shortfalls in our main region, Europe. With softer sales and our cost base geared for growth, our margins dropped to a level that requires rigorous cost management at all levels and a new style of resolute leadership to implement change expediently and consistently. We have taken measures to address this and are determined to improve our operating margin to a significantly higher level in the mid term. The Board is confident that, with the addition of Marco Gadola as new CEO, the organization will deliver this." BUSINESS PERFORMANCE Amid tough conditions in Europe and parts of Asia, Straumann's implant business succeeded in stabilizing sales at the prior year's level. The restorative business (CADCAM/digital) was slower in 2012 compared to the strong previous year. By contrast, Straumann's smallest business, Regeneratives, posted good growth. European recovery not yet in sight Economic deterioration, austerity and high unemployment, especially in southern Europe, dampened consumer confidence, reducing traffic at dental practices and leading patients to delay treatment or take cheaper, inferior options. Large markets like Spain and Italy, which are fragmented and highly permeated by cut-price competitors, suffered the biggest declines as the gap widened between markets in depressed economies and those in more prosperous areas. European revenues dipped 5% (l.c.) to CHF 378 million, corresponding to 55% of the Group total. The currency effect was negative but amounted to just 1 percentage point, helped by the minimum Euro exchange rate set by the Swiss National Bank. Growth continues in North America Straumann's second largest region, North America, achieved solid full-year growth of 6% (l.c.). After years of decline, the US dollar picked up against the Swiss franc, lifting growth by 6 percentage points to 12% in Swiss francs. As a result, revenue in North America reached a record CHF 174 million, corresponding to 25% of Group revenue. This performance was driven by solid demand for implants and regeneratives. Mixed picture in Asia/Pacific 15% or CHF 104 million of Group revenue was generated in Asia/Pacific. This was stable year on year in local currencies but up 3% in Swiss francs thanks to currency tailwind. The largest regional market, Japan, was dragged down by a weakening economy and damaging media reports about implant dentistry, from which it will take time to recover. The Korean market, which is highly penetrated and saturated by cut price local manufacturers continued to be very challenging. As noted previously, China was the region's key performer - with strong growth throughout. Rest of the World (RoW) overshadowed by turmoil in Middle East The region referred to as the 'Rest of the World' contributes approximately 4% of Group revenue, most of which is generated in Brazil, Mexico, and the Middle East. In 2012, revenue declined 3% in l.c. or 7% in Swiss francs, to CHF 31 million. The contraction was due largely to the Middle East, where dentistry like many other sectors, has suffered the effect of socio/political upheaval, embargoes, and cuts in private and government spending. By contrast, the largest market in the RoW region, Brazil, generated strong growth - both for Straumann and for Neodent. REVENUE BY REGION (in CHF million) Q4 2012 Q4 2011 FY 2012 FY 2011 Europe 93.7 100.7 378.1 404.4 Change in CHF% (7.0) (9.2) (6.5) (9.1) Change in l.c.% (6.3) (3.4) (5.1) 0.2 North America 43.3 42.4 173.7 155.6 Change in CHF% 2.1 2.8 11.7 (5.5) Change in l.c.% 0.0 12.0 6.4 10.2 Asia / Pacific 24.4 25.0 103.9 100.7 Change in CHF% (2.1) 3.0 3.2 0.2 Change in l.c.% (1.0) 5.7 (0.3) 5.5 Rest of the World (ROW) 6.4 7.5 30.5 32.9 Change in CHF% (14.9) 4.7 (7.3) 19.6 Change in l.c.% (10.4) 11.1 (3.0) 26.0 GROUP 167.8 175.6 686.3 693.6 Change in CHF% (4.4) (4.4) (1.1) (6.0) Change in l.c.% (4.2) 1.8 (1.6) 4.1 Change in l.c. % (excl. iTero4) (3.3) (1.0) OPERATIONS AND FINANCES Gross margin improves to 78% Excluding exceptionals of CHF 3 million, gross profit stood at CHF 534 million, CHF 6 million higher than in 2011, thanks to price increases, manufacturing efficiency gains, and a favorable business mix (lower scanner sales). Collectively these compensated for the reduction in volumes. The corresponding gross margin thus expanded 170 base points to 78%. Operating profit excluding exceptionals reaches almost 15% Reported Selling, General & Administrative (SG&A) costs rose to CHF 424 million mainly due to a goodwill impairment of CHF 21 million - related to an up-scaling of the Regenerative business - and a charge of CHF 15 million - related to the cost optimization program and severances. Excluding these exceptionals, SG&A increased CHF 16 million to CHF 387 million; CHF 5 million of the increase were related to the reorganization project and the Neodent transaction in the first half of the year. Research & Development investments increased to CHF 49 million or 7% of revenue, reflecting the Group's commitment to innovation. It also reflects the fact that Straumann has expanded its development activities in digital solutions, in addition to maintaining a stocked pipeline. Due to the abovementioned items, earnings before interest, tax, depreciation, amortization (EBITDA) and before exceptionals slid CHF 27 million to CHF 130 million, or 19% of sales. After ordinary amortization and depreciation charges of approximately CHF 35 million, operating profit (EBIT) excluding exceptionals amounted to CHF 100 million in comparison with CHF 120 million in 2011. Currency movements had no significant impact. The corresponding EBIT margin was 15%, slightly less than 3 percentage points lower than in the prior year. Net profit constrained by impact of exceptionals The net financial result was slightly positive compared with a negative CHF 2 million in 2011. The contributions from Neodent and Dental Wings (of which Straumann holds 49% and 44% respectively) are disclosed in the income statement under 'share of result from associates'. Together they contributed a positive CHF 7 million. However, considering amortization charges resulting from the purchase-price allocation, the share of profit from the two entities was a negative CHF 6 million5. Going forward, these investments are expected to be accretive to IFRS earnings in 2013. Income taxes came to CHF 19 million, CHF 12 million higher than in 2011, when the tax rate of 9% was considerably reduced as a result of the impairment in Japan. Taking the aforementioned factors and exceptionals into account, reported net profit amounted to CHF 36 million, with the corresponding margin reaching 5%. Basic earnings per share amounted to CHF 2.36. Improved working capital Net cash from operating activities decreased 18% to CHF 115 million, owing to: higher tax payments in the period, severance contributions, and increased operating expenses. Year on year the 'change in net working capital' improved by CHF 7 million due to a reduction in trade receivables and an increase in payables. With capital expenditure remaining more or less constant at CHF 19 million, free cash flow amounted to CHF 95 million and the respective margin was 14%. The purchase consideration for the 49% stake in Neodent amounted to CHF 261 million. Straumann also paid CHF 5 million for the 14% increase in its stake in Dental Wings. These were paid in cash. The equity ratio amounted to 82% at the end of 2012. Net cash used for financing activities totaled CHF 63 million after the payment of CHF 58 million for the ordinary dividend. Consequently, cash and cash equivalents at the end of 2012 amounted to CHF 141 million. Unchanged dividend The Board of Directors will propose an ordinary dividend of CHF 3.75 per share to the Shareholders at the Annual General Meeting on 5 April 2013. Cost reductions from headcount reduction to appear in 2013 In the fourth quarter, the Group announced a reduction of 150 positions worldwide - through transfers, natural fluctuation, early retirement and redundancies. The latter have been approached with due regard to the company's social responsibilities. Initial reductions were made in 2012 with the remainder to follow in 2013. OUTLOOK 2013 (barring unforeseen circumstances) Straumann's performance is expected to face continuing constraints due to the economy and consumer sentiment in Europe, while growth markets like North America, China and Brazil should continue to perform well. Straumann will continue to invest selectively in such growth markets. Based on the overall business fundamentals, strategic plan and the outcome of its cost optimization program, the Group assumes that it will be able to deliver improved profit levels in 2013, even if the market remains sluggish. In the mid term, it aims to return to solid growth and a significantly higher operating margin. Annual Report 2012 The pre-print version of Straumann's 2012 Annual Report is now available at annualreport.straumann.com as well as through the Media and Investors pages at www.straumann.com. About Straumann Headquartered in Basel, Switzerland, Straumann (SIX: STMN) is a global leader in implant, restorative and regenerative dentistry. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately 2500 people worldwide and its products and services are available in more than 70 countries through its broad network of distribution subsidiaries and partners. Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland. Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01 E-mail: firstname.lastname@example.org or email@example.com Homepage: www.straumann.com Contacts: Corporate Communication: Mark Hill +41 (0)61 965 13 21 Thomas Konrad +41 (0)61 965 15 46 Investor Relations: Fabian Hildbrand +41 (0)61 965 13 27 Disclaimer This release contains certain 'forward-looking statements', which can be identified by the use of terminology such as 'future', 'vision', 'assumption', 'will', 'goal', 'opportunity', 'long-term', 'value creation', 'potential', 'propose', 'well positioned', 'to succeed', 'aims', 'continue', 'outlook', or similar wording. Such forward-looking statements reflect the current views of management and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Group to differ materially from those expressed or implied. These include risks related to the success of and demand for the Group's products, the potential for the Group's products to become obsolete, the Group's ability to defend its intellectual property, the Group's ability to develop and commercialize new products in a timely manner, the dynamic and competitive environment in which the Group operates, the regulatory environment, changes in currency exchange rates, the Group's ability to hire and retain key talented individuals, to generate revenues and profitability, to realize its expansion projects in a timely manner, and to maintain its business relationships with suppliers, customers and other third parties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this report. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in it as a result of new information, future events or otherwise. Media and analysts' conference Straumann's full-year 2012 financial results conference will take place at 10.00h Swiss time in Basel today. The event will be webcast live on the internet (www.straumann.com/webcast). The recorded webcast will be available for the next month. Presentation slides The corresponding conference visuals are available at www.straumann.com/Straumann-2012-FY-Presentation.pdf and on the Media and Investors pages at www.straumann.com. Annual Report 2012 The pre-print version of Straumann's 2012 Annual Report is available under the following link annualreport.straumann.com and on the Media and Investors pages at www.straumann.com. In addition, the conference can also be accessed by telephone at the following dial-in numbers: +41 (0) 91 610 56 09 (Europe & RoW) +44 (0) 203 059 58 62 (UK) +1 (1) 866 291 41 66 (USA) Upcoming corporate/investor events 26 February 2013 Investor meetings, Zurich 05 April 2013 2013 Annual General Meeting ('Congress Center', Basel) 25 March 2013 Exane BNP Paribas Healthcare conference, Paris 26 March 2013 Investor meetings, London 27 March 2013 Investor meetings, Edinburgh 09 April 2013 Dividend ex-date 12 April 2013 Dividend payment date 30 April 2013 First quarter results (webcast/conference call) 02 May 2013 Investor meetings, Frankfurt 28 May 2013 Investor meetings, New York 29 May 2013 Investor meetings, Toronto 30 May 2013 Deutsche Bank Healthcare conference, Boston 20 August 2013 Half-year results conference, Basel Details on upcoming investor relations activities are published on www.straumann.com (Investors > Events). Straumann Media Releases subscription: www.straumann.com/en/home/investor-relations/ir-contacts-and-services/subscription.html RSS feed subscription: www.straumann.com/en/home/media/media-releases.news.rss 1 In this release 'exceptionals' comprise the following: In 2011, the impairment of intangible assets in Japan of CHF 40m (and related tax effect); in 2012, the goodwill impairment of CHF 21m relating to the global regenerative business; and charges of CHF 18m related to the Group's cost optimization program and severances. 2 Growth corrected to accommodate the discontinuation of distribution of iTero intra-oral scanners announced in October 2012. 3 Defined as net cash from operating activities less capital expenditures plus net proceeds from property, plant and equipment. 4 Growth corrected to accommodate the discontinuation of distribution of iTero intra-oral scanners announced in October 2012. 5 In 2012, the IFRS value was particularly impacted by a one-time expense on the fair-value adjustment of the inventory. 2012 Full-year results - Media Release (Download) Provider Channel Contact Tensid Ltd., Switzerland newsbox.ch Provider/Channel related enquiries www.tensid.ch www.newsbox.ch firstname.lastname@example.org +41 41 763 00 50
Israel Shoots Down Syrian Warplane Near Border, Army Says
Straumann reports full-year revenues of CHF 686m
Press spacebar to pause and continue. Press esc to stop.